Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):1153-1159. doi: 10.1051/medsci/2019219. Epub 2020 Jan 6.

[Biomanufacturing of monoclonal antibodies].

[Article in French; Abstract available in French from the publisher]

Author information

1
Centre de recherche sur les thérapeutiques en santé humaine, Conseil national de recherche du Canada, Montréal, Québec H4P 2R2, Canada.
2
Laboratoires français du fractionnement et des biotechnologies, Les Ulis, Courtaboeuf Cedex, France.
3
Centre de recherche sur les thérapeutiques en santé humaine, Conseil national de recherche du Canada, Montréal, Québec H4P 2R2, Canada - Département de biochimie et médecine moléculaire, Université de Montréal, Montréal, Québec H3C 3J7, Canada.

Abstract

in English, French

Antibody-based drugs are an increasingly important part of the therapeutic arsenal against a wide variety of medical conditions. As the number of commercial products and pipeline candidates grows, a crucial issue facing the industry is the current and future state of biomanufacturing. The productivity of the protein expression platforms, along with the performance of the technologies impacting upstream and downstream bioprocessing, are critical factors affecting the cost and time of therapeutic antibody development and commercialization. Cell engineering strategies are being used to improve the production of antibodies and to better control their quality in terms of posttranslational modifications, in particular with regards to their glycosylation state, as this can influence their therapeutic activity. Additionally, the advance of "omics" technologies have recently given rise to new possibilities in improving these expression platforms. We review here the various advances in biomanufacturing essential to the continued growth of the therapeutic antibody market.

PMID:
31903930
DOI:
10.1051/medsci/2019219

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center